RBC Capital Maintains Sector Perform on IGM Biosciences, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on IGM Biosciences (NASDAQ:IGMS) and increased the price target from $8 to $9.
December 06, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains a 'Sector Perform' rating on IGM Biosciences and raises the price target from $8 to $9.
The increase in price target by RBC Capital suggests a positive outlook on the stock's value, which may lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100